← All trials
NCT04311957
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2020
- Primary completion
- May 31, 2022
- Completion date
- Nov 30, 2022
- First posted
- Mar 17, 2020
- Last posted
- Mar 17, 2020
- Enrollment
- 386
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Haitian Group for the Study of Kaposi's Sarcoma and OpportunisticLead sponsor
- Cornell UniversityCollaborator
- Harvard UniversityOverall official - principal investigator
- Harvard UniversityCollaborator
- Harvard UniversityCollaborator
- Analysis Group, Inc.Collaborator
- Haitian Group for the Study of Kaposi's Sarcoma and OpportunisticOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.